S'abonner

Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa - 23/11/17

Doi : 10.1016/j.jaad.2017.07.027 
Iltefat H. Hamzavi, MD a, Murali Sundaram, PhD b, Cynthia Nicholson, MD a, Marko Zivkovic, PhD c, Angela Parks-Miller a, Jianyi Lee, PhD c, Jingbo Yi, MPH c, Yihua Gu, PhD b, Martin M. Okun, MD d, Arijit Ganguli, PhD b, Steve R. Arikian, MD c,
a Department of Dermatology, Henry Ford Hospital, Detroit, Michigan 
b AbbVie Inc, North Chicago, Illinois 
c Genesis Research, Hoboken, New Jersey 
d Fort HealthCare, Fort Atkinson, Wisconsin 

Reprint requests: Steve R. Arikian, MD, 5 Marine View Plaza, Hoboken, NJ 07030.5 Marine View PlazaHobokenNJ07030

Abstract

Background

Psoriasis and hidradenitis suppurativa (HS) exhibit distinct clinical features, but no studies have directly compared the health-related quality of life (HRQoL) in patients with moderate-to-severe manifestations of these conditions.

Objective

To determine which disease is associated with more severe HRQoL impairment.

Methods

Weighted averages of each of the following baseline HRQoL measures were determined and compared between HS and psoriasis populations from 5 clinical trials: Visual Analog Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index; EuroQOL 5D VAS, and Short Form-36 Health Survey.

Results

Compared with patients with psoriasis, patients with HS reported higher scores for VAS-pain (54.3 vs 36.1 [P < .0001]), Dermatology Life Quality Index (15.3 vs 11.3 [P < .0001]), EuroQOL 5D VAS (58.8 vs 50.8 [P < .0002]), and Total Work Productivity Impairment (35.4 vs 18.2). Patients with HS had lower Short Form-36 Health Survey scores than did patients with psoriasis (physical, 39.6 vs 49.0; mental, 41.5 vs 47.5 [both P < .0001]).

Limitations

This analysis was performed using published summary data rather than patient-level data, and weighted pooled averages were compared.

Conclusions

Patients with HS have a higher HRQoL burden than patients with psoriasis. This study clearly documents the needs of patients with HS and the potential impact of medical, scientific, and societal consensus for the development of more effective HS treatments.

Le texte complet de cet article est disponible en PDF.

Key Words : burden, DLQI, EQ-5D VAS, hidradenitis suppurativa, psoriasis, quality of life, SF-36, TWPI, VAS-pain

Abbreviations used : DLQI, EQ-5D, HRQoL, HS, MCS, PCS, SD, SF-36, TWPI, VAS-pain, WPAI


Plan


 Design, study conduct, and financial support for the study were provided by AbbVie Inc, which participated in interpretation of the data and review and approval of the manuscript. All authors contributed to the development of the publication and maintained control over the final content.
 Disclosure: Dr Hamzavi has served or currently serves as an investigator in clinical trial activities for AbbVie Inc, Adelphi Values, and The Microdermis Corporation, with research grants paid to his institution, and he is also the current president of the Hidradenitis Suppurativa Foundation in a nonfunded position. Drs Arikian, Zivkovic, and Lee and Ms Yi have current consulting agreements with AbbVie Inc. Dr Okun is a consultant to United BioSource Corporation (UBC), serves on the speaker's bureau for AbbVie Inc, is a former AbbVie employee, and may have owned AbbVie Inc, stock or stock options. Drs Ganguli and Yihua Gu are employees of AbbVie Inc, and may own AbbVie Inc, stock or stock options. Dr Sundaram is a former employee of AbbVie Inc, and may have owned AbbVie Inc stock or stock options. Ms Parks-Miller serves or has served on an advisory board for AbbVie Inc, has a current consulting agreement with AbbVie Inc, receives funding as the national coordinator of advocacy and support for the Hidradenitis Suppurativa Foundation, and is the founding director of Hope for Hidradenitis Suppurativa. Dr Nicholson is a nonfunded committee member for the Hidradenitis Suppurativa Foundation.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 77 - N° 6

P. 1038-1046 - décembre 2017 Retour au numéro
Article précédent Article précédent
  • Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials
  • Kenneth B. Gordon, Keith A. Betts, Murali Sundaram, James E. Signorovitch, Junlong Li, Meng Xie, Eric Q. Wu, Martin M. Okun
| Article suivant Article suivant
  • Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa
  • Guy Shalom, Meir Babaev, Tamar Freud, Shmuel Tiosano, Nadav Pam, Amir Horev, Jacob Dreiher, Daniel A. Vardy, Doron Comaneshter, Arnon D. Cohen

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.